The IBS Private Equity Growth Fund II had a successful final closing with €113.5 million in committed capital. Over 165 IBS clients have committed to this new IBS Private Markets fund.
The IBS Private Equity Growth Fund II invests in four high-quality primary private equity funds. After the first closing, the underlying IBS Vantage Point Co-investment Fund I has also started. From this fund, we will make co-investments with the four managers in the IBS Private Equity Growth Fund II and with other private equity managers from the IBS network.
The IBS fund is expected to:
The four private equity funds offer you a well-diversified portfolio with 40 to 50 underlying companies. In addition, we will invest directly in 10 to 12 companies through co-investments. The combination offers a full allocation to the primary private equity segment.
The underlying strategies focus on the ‘middle market’ private equity segment. These are growth companies in the life cycle phase before an IPO or resale to a larger investor. This market segment is characterized by lower valuations, lower debt levels and high growth potential. Together, these factors can yield very attractive returns.
The emphasis is on profitable companies with a high-quality business model that benefit from structural technological or demographic growth trends. Think of technology, healthcare, automation, B2B services and fintech.
Co-investments are exclusive invitations from private equity managers to invest directly in companies. We have written a blog on this topic.
The co-investment allocation to the underlying IBS Vantage Point Co-investment Fund I gives us the opportunity to select direct investments from the deal flow of the four private equity funds. In addition, the co-investment fund can make co-investments with other private equity managers in the IBS network. This puts us in an even better position to leverage our entire private equity network. On average, co-investments generate even higher returns than fund investments, partly because you do not have to pay management and performance fees on the co-investments.
Please note: investing involves risks. You can lose your investment. Past performance is not a guarantee of future performance.
This investment institution falls under the exemption from the prospectus obligation because of the minimum participation of €250,000. Although the prospectus has been approved by the AFM, this does not mean that the AFM recommends or approves the investment.
This investment institution has a high risk profile. Please read the Key Information Document (EID) and prospectus before you decide to participate. These documents are available from the manager, IBS Fund Management B.V., via the website ibsfm.nl.
The prospectuses of the closed-end investment funds managed for IBS Fund Management B.V. and those of the underlying master investment funds are available at the request of the participants (in the secure part of the site and via [email protected]).
